The peptide drug conjugates market size is estimated to be USD 601.56 million in 2022 and is expected to witness a CAGR of 18.68% during the forecast period 2023-2033. Expanding healthcare spending and growing geriatric population are projected to drive the market growth in near future. Furthermore, rising financial research and development investments and a strong product pipeline and increasing prevalence of diseases including cancer and viral disease are other factors supporting the market growth. However, expensive treatments, complicated procedures, and inadequate regulatory regulations are predicted to limit market growth are expected to restrain the market growth.

Rising financial research and development investments and a strong product pipeline is expected to propel the market growth during the projected period. For instance, phase 3 clinical studies are being conducted on the product candidate for a tumour developed by Angio Chem, Inc., and phase 2 clinical studies are being performed on the pipeline products for non-small cell carcinoma developed by Bicycle Therapeutics, BT5528 and BT1718.

Increasing prevalence of diseases including cancer and viral disease is predicted to fuel the market growth during the forecast period. According to a National Center for Biotechnology Information article that cited GLOBOCAN cancer statistics predictions of prevalence and mortality worldwide for the year 2020, there were 9.9 million cancer-related deaths and 19.3 million new cases of cancer reported worldwide. Furthermore, by 2040, there will be 28.4 million new cases of cancer worldwide.

Segmentation

By Product

The market is categorized into melflufen, CBX-12, lutetium, BT1718, ANG1005, and others. In 2022, the lutetium segment accounted for the highest revenue share due to the growing product approval and its launches. Lutathera (lutetium Lu 177) from Novartis, an advanced accelerator injectable and radiolabeled somatostatin analogue, is the first PDC to get FDA approval. The estimated patent expiration date is July 25, 2038. It is approved for the treatment of people with gastro enteropancreatic neuroendocrine cancers that exhibit the somatostatin receptor, including those of the midgut, foregut, and hindgut. The radiotherapeutic substance 177Lu and the homing peptide somatostatin are associated by an amide in lutathera. In February 2021, Oncopeptides AB got FDA approval for Pepaxto (melflufen), a peptide-conjugated alkylator that is a first-in-class. For adult patients with multiple myeloma, Pepaxto (Melphalan flufenamide) and dexamethasone are recommended.

By Type

The market is categorized into diagnostic and therapeutic. In the global market, the therapeutic segment accounted for the largest revenue share in 2022 owing to availability of both approved PDCs, Lutathera and Pepaxtoas therapeutic drugs targeting tumor cells. The clinical studies for BT5528 and BT1718 are anticipated to enhance the market during the projection period. The pharmaceutical companies are also developing therapeutic PDCs with a focus on metabolic disorders and coronavirus diseases in addition to cancer due to the enormous advantages of PDCs in the therapeutic segment. PDCs and radionucleotides can both be used as diagnostic tools. For instance, the radioactive nucleotide-containing drug In-DTPA-octreotide (octreoscan) from Mallinckrodt Pharmaceuticals is largely used to localize neuroendocrine tumors. Furthermore, it is projected that the expansion of the segment would be profitable due to the development and uses of PDCs in diagnosis.

Regional Markets

In 2022, North America region accounted for the highest revenue in the peptide drug conjugates market and is expected to maintain its dominance during the forecast period. This is attributed to introduction of Melflufen and the fast adoption of PDC drugs in cancer therapy. The factors anticipated to propel market expansion include improved patient accessibility, favourable reimbursement policies, and rising awareness of available treatment alternatives. Furthermore, the region’s market is expanding due to an increase in cancer incidence and deaths associated with it. For instance, the NCI estimated that there would be 1,806,590 new cases of cancer and 606,520 deaths from disease in 2020. Asia Pacific is anticipated to grow over the course of the projection period. The increase in cancer cases and the strategic actions made by market participants for regional expansion in these regions are credited with the region’s growth. The market expansion in the region is also projected to be boosted by expanding research and development along with rising investments to create and market such novel delivery systems.

Competitor Insights

Some of the key players operating in the peptide drug conjugates market are AstraZeneca, Esperance Pharmaceuticals, Validus Pharmaceuticals LLC, Peptron, Inc., Dauntless Pharmaceuticals, CRINETICS PHARMACEUTICALS, Bicycle Therapeutics, Cybrexa Therapeutics, Camurus AB, Ipsen Pharma, Oncopeptides AB, Pfizer Inc, Pepgen Corporation, Novartis AG, Chiasma, Inc., Theratechnologies, Antisense Therapeutics, Midatech Pharma PLC, and Soricimed Biopharma.

• The collaboration agreement offering Exelixis the chance to acquire the first-in-class peptide-drug conjugate (PDC), CBX-12, was announced by Cybrexa Therapeutics and Exelixis, Inc. in November 2022. The trial pipeline for the targeted medication therapy is anticipated to grow as a result of this initiative.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product and type from 2022 to 2033.

Report Scope:

Segmentation: Peptide Drug Conjugates Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Melflufen
• CBX-12
• Lutetium
• BT1718
• ANG1005
• Others

Type (Revenue, USD Million), 2022 – 2033

• Diagnostic
• Therapeutic

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA